Genexine Inc (095700)

Currency in KRW
5,280
-140(-2.58%)
Closed·
095700 Scorecard
Full Analysis
Stock has taken a big hit over the last week
095700 is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
5,2305,440
52 wk Range
3,51010,230
Key Statistics
Bid/Ask
5,270.00 / 5,280.00
Prev. Close
5,280
Open
5,420
Day's Range
5,230-5,440
52 wk Range
3,510-10,230
Volume
335.39K
Average Volume (3m)
371.79K
1-Year Change
-26.18%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
095700 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Suffers from weak gross profit margins

Genexine Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Genexine Inc Company Profile

Genexine, Inc., together with its subsidiaries, operates as a biotechnology company that focuses on the development and commercialization of immunotherapies in South Korea and internationally. The company develops its products through its hybrid Fc platform, a proprietary technology designed to develop long-acting protein drugs; and the DNA vaccine platform that is used to elicit immune responses in the human body to fight viral infection and cancer cells. Its product pipeline includes GX-H9, which is in Phase II and III clinical trials for the treatment of adult and pediatric growth hormone deficiency; GX-E4 that is in Phase III clinical trials for the treatment of anemia; GX-G3, which is in Phase II clinical trials to treat neutropenia; GX-I7, a product candidate in Phase I and II clinical trials to treat solid tumors, lymphopenia, and COVID-19; GX-P1, which is in Phase I clinical trials for the treatment of autoimmune diseases and transplantation; and GX-G6 that is in Phase II clinical trials for the treatment of diabetes. The company is also developing GX-188E that is in Phase II clinical trials for the treatment of cervical cancer, and head and neck cancer. The company was formerly known as Genexine Co., Ltd. and changed its name to Genexine, Inc. in March 2013. Genexine, Inc. was founded in 1999 and is headquartered in Seoul, South Korea.

Compare 095700 to Peers and Sector

Metrics to compare
095700
Peers
Sector
Relationship
P/E Ratio
0.0x−4.8x−0.5x
PEG Ratio
0.00−0.090.00
Price/Book
0.0x2.3x2.6x
Price / LTM Sales
0.0x19.3x3.2x
Upside (Analyst Target)
0.0%23.6%41.6%
Fair Value Upside
Unlock−1.1%6.0%Unlock

Earnings

Latest Release
May 19, 2025
EPS / Forecast
-- / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

095700 Income Statement

People Also Watch

12,150
005690
-2.64%
68,500
065350
-0.72%
3,780
099440
+0.27%
5,550
200230
-0.54%

FAQ

What Stock Exchange Does Genexine Trade On?

Genexine is listed and trades on the KOSDAQ stock exchange.

What Is the Stock Symbol for Genexine?

The stock symbol for Genexine is "095700."

What Is the Genexine Market Cap?

As of today, Genexine market cap is 240.13B.

What Is Genexine's Earnings Per Share (TTM)?

The Genexine EPS (TTM) is -1,320.62.

When Is the Next Genexine Earnings Date?

Genexine will release its next earnings report on 18 Aug 2025.

From a Technical Analysis Perspective, Is 095700 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.

How Many Times Has Genexine Stock Split?

Genexine has split 2 times.

How Many Employees Does Genexine Have?

Genexine has 86 employees.

What is the current trading status of Genexine (095700)?

As of 28 Jul 2025, Genexine (095700) is trading at a price of 5,280.00, with a previous close of 5,280.00. The stock has fluctuated within a day range of 5,230.00 to 5,440.00, while its 52-week range spans from 3,510.00 to 10,230.00.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.